COST-EFFECTIVENESS OF HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV-7) IN MEXICO

Author(s)

Carlos F1, Mercado G2, Aguirre A2, Vargas A1, Bierschwale H21R A C Salud Consultores, SA de CV, Ciudad de Mexico, Distrito Federal, Mexico, 2Wyeth México, Naucalpan, Mexico

OBJECTIVES: Streptococcus pneumoniae is one of the most frequent causes of invasive(IPD) and non-invasive infections(Non-IPD), causing 1.6 million deaths worldwide in 2002. PCV-7 provides a reliable protection for children ≤2 years old.We aimed to perform an economic evaluation of three doses plus a booster (3+1) compared to an abbreviated scheme (2+1) and with non-vaccination. METHODS: We developed a Markov model of ten annual cycles to estimate the costs and outcomes for a birth cohort of 1,955,284. Another model was designed to estimate the herd immunity effects during a year in the non-vaccinated population,98% coverage rate was assumed.Efficacy data from published sources was adjusted by serotype coverage and all costs reflect local practice.Direct medical costs included the immunization program, medical attention of IPD/Non-IPD and sequels of meningitis.All costs (discounted with an annual rate of 5%) were calculated in 2008 Mexican Pesos (MXP) and then expressed in US dollars (USD) using an exchange rate of 1 USD to 11.14 MXP (exchange rate by the time the study was performed).Disability-adjusted life years (DALY) were estimated following standard methods and assumptions. RESULTS: For the vaccinated cohort, the full scheme is a cost-saving intervention, costing US$10 million less than the abbreviate scheme and US$51 million less than non-vaccination. Adding the herd immunity benefits, overall savings increases to US$17.40 million (benefit:cost ratio 1.08) compared to (2+1) scheme and reaches US$121.19 million (benefit:cost ratio 1.54) compared with non-vaccination.The DALY averted with the full scheme are 35,988 and 172,813 compared to (2+1) scheme and non-vaccination, respectively. CONCLUSIONS: The full scheme (3+1) of PCV-7 had lower costs and better health outcomes when compared to both an abbreviated scheme (2+1) and non-vaccination, even if herd immunity is not taken into account.Although the 3+1 schedule is dominant the 2+1 schedule remains highly cost effective vs. no vaccination at all.

Conference/Value in Health Info

2009-10, ISPOR Europe 2009, Paris, France

Value in Health, Vol. 12, No. 7 (October 2009)

Code

PIN16

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Infectious Disease (non-vaccine), Vaccines

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×